Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2006 1
2007 2
2009 1
2011 1
2012 2
2013 5
2014 1
2015 1
2019 1
2020 2
2021 4
2022 8
2023 5
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

35 results

Results by year

Filters applied: . Clear all
Page 1
National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide.
Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. Shaw BE, et al. Among authors: hardy nm. J Clin Oncol. 2021 Jun 20;39(18):1971-1982. doi: 10.1200/JCO.20.03502. Epub 2021 Apr 27. J Clin Oncol. 2021. PMID: 33905264 Free PMC article. Clinical Trial.
Chimeric antigen receptor (CAR) T cells for the treatment of a kidney transplant patient with post-transplant lymphoproliferative disorder (PTLD).
Kline K, Chen W, Kallen ME, Koka R, Omili D, Fan X, Iraguha T, Gebru E, Dishanthan N, Baker JM, Dietze KA, Yared JA, Hankey K, Dahiya S, Niederhaus SV, Dunleavy K, Hardy NM, Luetkens T, Rapoport AP, Atanackovic D. Kline K, et al. Among authors: hardy nm. Hum Vaccin Immunother. 2023 Aug 1;19(2):2216116. doi: 10.1080/21645515.2023.2216116. Epub 2023 Jun 6. Hum Vaccin Immunother. 2023. PMID: 37278257 Free PMC article.
Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial.
Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. Shaw BE, et al. Among authors: hardy nm. Transplant Cell Ther. 2023 Mar;29(3):208.e1-208.e6. doi: 10.1016/j.jtct.2022.12.017. Epub 2022 Dec 27. Transplant Cell Ther. 2023. PMID: 36584941 Free PMC article.
Immune-mediated facial nerve paralysis in a myeloma patient post B-cell maturation antigen-targeted chimeric antigen receptor T cells.
Kathari YK, Ahmad H, Kallen ME, Koka R, Omili D, Iraguha T, Clement J, Pham L, Khalid M, Fan X, Gebru E, Lesho P, Park E, Dishanthan N, Baker JM, Dietze KA, Hankey KG, Badros A, Yared JA, Dahiya S, Hardy NM, Kocoglu H, Luetkens T, Rapoport AP, Atanackovic D. Kathari YK, et al. Among authors: hardy nm. Haematologica. 2024 Feb 1;109(2):682-688. doi: 10.3324/haematol.2023.283296. Haematologica. 2024. PMID: 37675514 Free PMC article. No abstract available.
Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by 18F-FDG PET/CT Imaging Following CAR-T Therapy.
Lutfi F, Goloubeva O, Kowatli A, Gryaznov A, Kim DW, Dureja R, Margiotta P, Matsumoto LR, Bukhari A, Ahmed N, Mushtaq MU, Law JY, Lee ST, Kocoglu MH, Atanackovic D, Yared JA, Hardy NM, McGuirk JP, Rapoport AP, Chen W, Dahiya S. Lutfi F, et al. Among authors: hardy nm. Clin Lymphoma Myeloma Leuk. 2023 Oct;23(10):757-763. doi: 10.1016/j.clml.2023.06.005. Epub 2023 Jun 19. Clin Lymphoma Myeloma Leuk. 2023. PMID: 37453865 Free article.
Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (CAR) T cells.
Kline K, Luetkens T, Koka R, Kallen ME, Chen W, Ahmad H, Omili D, Iraguha T, Gebru E, Fan X, Miller A, Dishanthan N, Baker JM, Dietze KA, Hankey KG, Yared JA, Hardy NM, Rapoport AP, Dahiya S, Atanackovic D. Kline K, et al. Among authors: hardy nm. Cancer Immunol Immunother. 2024 Feb 13;73(3):45. doi: 10.1007/s00262-023-03619-9. Cancer Immunol Immunother. 2024. PMID: 38349430 Free PMC article.
Immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: predictive biomarkers and clinical outcomes.
Holtzman NG, Xie H, Bentzen S, Kesari V, Bukhari A, El Chaer F, Lutfi F, Siglin J, Hutnick E, Gahres N, Ruehle K, Ahmad H, Shanholtz C, Kocoglu MH, Badros AZ, Yared JA, Hardy NM, Rapoport AP, Dahiya S. Holtzman NG, et al. Among authors: hardy nm. Neuro Oncol. 2021 Jan 30;23(1):112-121. doi: 10.1093/neuonc/noaa183. Neuro Oncol. 2021. PMID: 32750704 Free PMC article. Review.
Impaired immune response to COVID-19 vaccination in patients with B-cell malignancies after CD19 CAR T-cell therapy.
Dahiya S, Luetkens T, Lutfi F, Avila S, Iraguha T, Margiotta P, Hankey KG, Lesho P, Law JY, Lee ST, Baddley J, Kocoglu M, Yared JA, Hardy NM, Rapoport AP, Atanackovic D. Dahiya S, et al. Among authors: hardy nm. Blood Adv. 2022 Jan 25;6(2):686-689. doi: 10.1182/bloodadvances.2021006112. Blood Adv. 2022. PMID: 34941995 Free PMC article. No abstract available.
Vaccine-induced T-cell responses against SARS-CoV-2 and its Omicron variant in patients with B cell-depleted lymphoma after CART therapy.
Atanackovic D, Luetkens T, Omili D, Iraguha T, Lutfi F, Hardy NM, Fan X, Avila SV, Saharia KK, Husson JS, Niederhaus SV, Margiotta P, Lee ST, Law JY, Mannuel HD, Vander Mause E, Bauman S, Lesho P, Hankey K, Baddley J, Kocoglu M, Yared JA, Rapoport AP, Dahiya S. Atanackovic D, et al. Among authors: hardy nm. Blood. 2022 Jul 14;140(2):152-156. doi: 10.1182/blood.2022016175. Blood. 2022. PMID: 35537186 Free PMC article.
Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed/refractory diffuse large B-Cell lymphoma.
Kim DW, Bukhari A, Lutfi F, Zafforoni F, Merechi F, Mustafa Ali MK, Gottlieb D, Lee ST, Kocoglu MH, Hardy NM, Yared J, Rapoport AP, Dahiya S, Law JY. Kim DW, et al. Among authors: hardy nm. Leuk Lymphoma. 2022 Jun;63(6):1339-1347. doi: 10.1080/10428194.2021.2024817. Epub 2022 Jan 19. Leuk Lymphoma. 2022. PMID: 35045791
35 results